Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infectious disease
Research
Shionogi offers $600M for Swiss biotech's antibiotic program
Shionogi and BioVersys will work together to develop new ansamycin candidates for nontuberculous mycobacteria infections.
Darren Incorvaia
Jul 2, 2025 1:00am
GSK snags longtime Sanofi exec to lead vaccine development
Jun 9, 2025 10:45am
GSK's bet on rejected UTI antibiotic pays off with phase 3 win
May 28, 2025 8:42am
Fierce Healthcare
Court blocks HHS RIF again after Trump's Supreme Court appeal
May 23, 2025 10:30am
Armata links bacteria-killing virus to responses in phase 2
May 19, 2025 8:41am
Trump aims to block pathogen research, citing ‘lab leak’ theory
May 6, 2025 9:05pm